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Abstract
Objective: To undertake an economic evaluation alongside the largest randomised controlled trial comparing
Levonorgestrel-releasing intrauterine device (‘LNG-IUS’) and usual medical treatment for women with menorrhagia in
primary care; and compare the cost-effectiveness findings using two alternative measures of quality of life.
Methods: 571 women with menorrhagia from 63 UK centres were randomised between February 2005 and July 2009.
Women were randomised to having a LNG-IUS fitted, or usual medical treatment, after discussing with their general
practitioner their contraceptive needs or desire to avoid hormonal treatment. The treatment was specified prior to
randomisation. For the economic evaluation we developed a state transition (Markov) model with a 24 month follow-up.
The model structure was informed by the trial women’s pathway and clinical experts. The economic evaluation adopted a
UK National Health Service perspective and was based on an outcome of incremental cost per Quality Adjusted Life Year
(QALY) estimated using both EQ-5D and SF-6D.
Results: Using EQ-5D, LNG-IUS was the most cost-effective treatment for menorrhagia. LNG-IUS costs £100 more than usual
medical treatment but generated 0.07 more QALYs. The incremental cost-effectiveness ratio for LNG-IUS compared to usual
medical treatment was £1600 per additional QALY. Using SF-6D, usual medical treatment was the most cost-effective
treatment. Usual medical treatment was both less costly (£100) and generated 0.002 more QALYs.
Conclusion: Impact on quality of life is the primary indicator of treatment success in menorrhagia. However, the most cost-
effective treatment differs depending on the quality of life measure used to estimate the QALY. Under UK guidelines LNG-
IUS would be the recommended treatment for menorrhagia. This study demonstrates that the appropriate valuation of
outcomes in menorrhagia is crucial.
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Introduction
Menorrhagia, or heavy menstrual bleeding, places a consider-
able burden on healthcare resources, with around 6% of women
per year consulting their general practitioners [1]. The condition
can be defined as ‘‘Excessive menstrual blood loss which interferes
with a woman’s social, emotional, physical and material quality of
life’’ [2]. Treatment is prompted predominantly by a woman’s
subjective assessment of interference in her quality of life, rather
than solely by clinical assessment of volume of blood loss [3].
Women may change, or cease treatment, according to their
perception of effectiveness, and relative to their contraceptive
needs.
Historically, women often progressed quickly to a surgical
solution; either hysterectomy, resulting in the permanent cessation
of bleeding and sterility, or since the 1990s, endometrial ablation,
which uses electrical or thermal energy to destroy the endome-
trium, causing amenorrhea in 34% of women [4]. Non-hormonal
and hormonal medical treatments are now available as first line
therapy for women presenting with menorrhagia in primary care.
In 2007, the National Institute of Health and Care Excellence
(NICE) introduced guidelines for the Levonorgestrel-releasing
intrauterine system (LNG-IUS) to be used for treatment of
menorrhagia based on limited evidence on cost-effectiveness [2;5].
Nine other small trials have compared LNG-IUS to non-hormonal
and hormonal treatments, showing reduction in menstrual blood
loss but these did not consider cost-effectiveness [6;3].
To our knowledge, no direct cost-effectiveness comparison of
LNG-IUS against usual medical treatment has been reported. We
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undertook an economic evaluation as part of the ECLIPSE trial
(Effectiveness and Cost-effectiveness of Levonorgestrel-containing
Intrauterine system in Primary care against Standard trEatment
for menorrhagia), a pragmatic, multicentre, randomised trial,
comparing the clinical and cost-effectiveness of LNG-IUS against
usual medical treatment in the primary care setting. Further, as
impact on quality of life is the primary outcome measure in
menorrhagia, quality of life was measured using two different
instruments including EQ-5D and SF-6D. Both instruments are
accepted measures for valuing health related quality of life,
although NICE’s preferred measure is EQ-5D [7]. Since
treatment is prompted by women’s own assessment of interference
on quality of life it was considered appropriate to explore the
influence on the cost-effectiveness results of using both instru-
ments.
Methods
We conducted a model-based economic evaluation in the form
of a cost-utility analysis, based on an outcome of cost per quality
adjusted life year (QALY) alongside the ECLIPSE trial [8]. The
QALY outcome encapsulates quality and quantity of life into a
single metric. The analysis was carried out from a UK National
Health Service (NHS) perspective in a primary care setting and
provides an assessment of the difference in costs and QALYs
between interventions over a 24-month time horizon. A second
analysis will be carried out at the 5-year time point. A societal
perspective to include private costs to women was considered but
deemed not to be feasible given the resource constraints for data
collection.
Participants and trial design
The ECLIPSE trial, which found LNG-IUS to be more effective
than usual treatment, is reported in detail elsewhere [8]. Briefly,
571 women with menorrhagia from 63 UK centres were
randomised between February 2005 and July 2009. Women
between 25 and 50 years of age presenting to their general
practitioner (GP) with menorrhagia, occurring over at least three
consecutive cycles, provided written informed consent to partic-
ipate. The definition of menorrhagia used is consistent with that
used in the RCOG guidelines and was the basis of the clinical
paper published in the New England Journal of Medicine [8;9].
Women were excluded if they intended to become pregnant over
the next 5 years, were taking hormone replacement therapy or
tamoxifen, had intermenstrual or post-coital bleeding or exami-
nation suggestive of fibroids (abdominally palpable uterus equiv-
alent in size to 10–12 weeks’ gestation) or other pathologies, or had
contraindications to, or a preference for, LNG-IUS or usual
medical treatments. Women were allocated to a treatment group
by telephone or web-based central randomisation service. Women
were randomised to having a LNG-IUS fitted, or usual medical
treatment, chosen by the GP and the woman based on
contraceptive needs or desire to avoid hormonal treatment.
Usual medical treatment options included mefenamic acid,
tranexamic acid, norethisterone, a combined estrogen/progesto-
gen or progestogen only oral contraceptive pill (any formulation),
or methoxyprogesterone acetate injection [2;9] The particular
medical treatment was specified prior to randomisation. Treat-
ment review by the GP at 6 weeks and 3 months was
recommended. Subsequently, treatments could be changed or
discontinued as per usual practice (e.g. due to perceived lack of
benefit, side effects, change in contraception need, referral for
endometrial ablation or hysterectomy) [2;9]. Treatment changes
reported by women were confirmed with the GP.
Ethical approval was obtained from the National Research
Ethics Service Committee South West - Exeter and clinical trial
authorization from the Medicines and Healthcare Regulatory
Authority. Written consent was obtained from the participants.
The name of the trial registry is ISRCTN and the number is
ISRCTN86566246.
Model
We developed a state transition (Markov) model in place of the
typical trial-based economic analysis to comprehensively account
for the changes in quality of life that occurred whilst the women
were taking these treatments.
As outlined later, data on utilities (or quality of life) were
collected at baseline, 6 months, 1 year and 2 years. The trial data
showed that, due to its non-curative nature, women were changing
their treatment, more frequently within this time, to identify the
best method for managing menorrhagia, and this process had an
influence on their quality of life. The analysis does not lend itself to
a regression framework because patients change between different
health states on a monthly basis and quality of life was not
measured at that frequency. It would therefore be inappropriate to
infer QALYs in a typical trial based analysis from the quality of life
scores at the time point they happen to be taken in the trial. The
most suitable method to capture changes in quality of life,
occurring throughout the trial, and provide a robust cost-utility
analysis, was to represent these experiences as health states in a
decision model, which follows the process of management of
menorrhagia used in the ECLIPSE trial. Therefore, quality of life
values were attached to the health states. A measure of change in
utility from baseline and the endpoint of the trial, as in a typical
trial-based analysis which does not use a decision model, would
not accurately capture the health states that women had
experienced throughout the time span of the trial. Furthermore,
a typical trial-based analysis, without a decision model, would not
comprehensively capture the time spent in health states or the
associated repetitive costs and resource use. The decision model,
based on trial data, provides a more realistic explanation of the
utility pathway, providing information that can be synthesised with
other data and projected forward. Specifically, a Markov model
appropriately combines data for each of the pathways and takes
account of the cyclical and repetitive nature of events and
facilitates a simulation approach. All parameters used in the model
were based on the trial data.
The model structure was informed by clinical input and the
pathways followed by the women in the ECLIPSE trial. Figure 1
presents the clinical pathways and the progress of the two cohorts
of women in the ECLIPSE trial who were randomised to LNG-
IUS or usual medical treatment. A monthly time cycle is used as
this represents the clinically meaningful changes observed in
treatment and resource use. The following assumptions were made
and developed based on clinical expertise from practising primary
care and gynaecology clinicians, in addition to standard treatment
protocol. The assumptions were agreed prior to conducting the
analysis.
Model assumptions
N A woman is ‘well’ with the allocated treatment if she does not
change or stop treatment. Some of these women may not be
‘well’ but are coping with treatment, and the utility values for
the ‘well’ with allocated treatment state reflect this.
N A woman who is ‘well with LNG-IUS’ or ‘well with usual
medical treatment’ cannot spontaneously become ‘symptom-
atic’.
Cost-Effectiveness of LNG-IUS for Menorrhagia
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N Based on the data, if in the first cycle, women move from the
allocated treatment to an alternative state other than ‘well’, it is
assumed they either move to the ‘change to alternative
treatment’ or the ‘no treatment’ state. We assume that they do
not move to the ‘symptomatic’ state in the first cycle because
insufficient time has elapsed to establish this and so it is
assumed they changed for other reasons.
N From the second cycle onwards, if women change from their
allocated treatment they do not go to ‘well’ but to the
‘symptomatic’ state and move on from there.
N For the transition to the ‘surgery’ state, data were collected on
whether a woman had ablation or hysterectomy, but not the
precise technique e.g. thermal balloon endometrial ablation or
microwave endometrial ablation. Data on the weighted
likelihood of surgery undertaken were taken from a previous
study [10]. In the model we assumed that if a woman in the
trial has endometrial ablation, it will be her first ablation and
we apply the cost for first line endometrial ablation techniques.
N Once a woman in the model has changed from the allocated
treatment, it is not possible for her to move back to the
allocated treatment.
N We assumed that if a woman ‘changes to the other treatment’,
she must spend at least one cycle in ‘change to other treatment’
before she can move to ‘well with other treatment’. This is
required because it will take at least one menstrual cycle for
any effect to become apparent.
Outcome measures
Outcome measures were collected using both EQ-5D and SF-
36 at baseline prior to randomisation, then by post at 6 months, 1
year and 2 years post-randomisation. The booklet questionnaire,
given to women in the trial, contained the generic EQ-5D-3L
questionnaire, which measures the impact of treatment on broader
aspects of health related quality of life [11]. SF-36 was converted
into SF-6D using the algorithm [12]. Utility values for each state in
the model were calculated by averaging the EQ-5D or SF-6D
values for each woman in the given state at any given time.
Utility values for the individual states were calculated by
averaging the EQ-5D (SF-6D) values obtained by each woman in
the given state at any given time. For example if a woman is
randomised to LNG-IUS and then does not change treatment she
is considered to be in the ‘well’ state for the remainder of the
analysis, as outlined in the model assumptions previously.
Therefore all of the woman’s utility values collected at 6 months,
1 year and 2 years will be assigned to the ‘well’ health state in the
model. Similarly if a woman is initially ‘symptomatic with LNG-
IUS’ and then moves to ‘no treatment’ at 2 years, the utility values
for 6 months and 1 year will be assigned to ‘symptomatic’ and the
utilities for 2 years assigned to the ‘no treatment’ health state. This
method was used to derive the utility values because the utility for
the state is important, not the values associated with the individual
woman’s journey, as decision models are a reflection of the typical
population.
Costs and Resource use
Costs were collected from a UK NHS perspective. Data on
healthcare resource use, including GP or gynaecologist consulta-
tions, were collected from women alongside other outcome
measures. The general healthcare costs for both groups included
healthcare staff costs and the cost of the interventions. An LNG-
IUS fitting was estimated to take 20 minutes (informed by clinical
experts within trial team), require both a GP and nurse to be
present and also require disposable consumables. Treatment
review by the GP was assumed to last 10 minutes (informed by
clinical experts within trial team). Staff costs were calculated using
nationally recognised reference costs [13]. The costs of standard
medical treatment and LNG-IUS were estimated from the British
National Formulary [14]. Cost data on surgical interventions were
taken from a previously published study and inflated to 2011 [10].
As recommended by NICE a discount rate of 3.5% was applied to
both costs and utilities as the model time horizon is beyond 1 year
[7]. All costs are reported in 2011 prices in UK (£) sterling using
the UK hospital and community health services index [13].
Tables 1–3 present the data used in the analysis.
In cases where women were prescribed a combination of the
usual medical treatments, a weighted average of the cost is taken.
Similarly, repeat prescription costs were calculated based on the
average weighted cost of repeat prescriptions in the ‘change to
usual medical treatment’ state of the LNG-IUS arm. As the most
Figure 1. Clinical pathway for LNG-IUS and usual medical treatment.
doi:10.1371/journal.pone.0091891.g001
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commonly prescribed usual medical treatments involved GP
review for effectiveness at 3 months, it was assumed that this
occurs at 3 months.
Analysis
An incremental cost-utility analysis provides information on the
difference in costs and QALYs between LNG-IUS and usual
medical treatment and is reported in terms of incremental cost-
effectiveness ratios (ICERs), as cost per QALY gained. If a
treatment is less costly and generates a greater number of QALYs,
dominance is said to occur. Analysis was by intention-to-treat to
provide a pragmatic estimate of ICERs. The base case analysis
and three deterministic sensitivity analyses were carried out using
EQ-5D. An additional sensitivity analysis, repeating the base case
and its three deterministic sensitivity analyses was carried out using
SF-6D.
Uncertainty in the model was explored by conducting both
deterministic and probabilistic sensitivity analysis. Population
heterogeneity was not considered by assessing the cost-effective-
ness according to population subgroups because the randomised
nature of the trial should mean that there are no systematic
differences between women in each treatment arm.
Deterministic Sensitivity Analysis:
1. We replaced the mean utility values for each state used in the
base case by the median utility value. Previously some
published studies used the median and not the mean value,
which greatly impacts the cost-effectiveness results and is
argued to be inappropriate [10]. The current analysis assesses
the impact of using such values when primary data are
collected.
2. We incorporated the assumptions used in the UK national
guidelines costing template to replace the expert opinion and
trial data that was used in the base case. This change applied to
the clinical staff member present for the initial consultation,
which used a practice nurse and was assumed to be 10 minutes
for the initial consultation and insertion (GP in the base case for
the initial consultation, and 20 minutes for the insertion with
both GP and practice nurse), treatment review by a nurse at 6
weeks (GP was used in the base case) only for those with a
LNG-IUS fitted and annual follow-up for both treatment
groups thereafter (no annual follow-up in the base case) [2].
3. In the base case, we assumed that when an EQ-5D completion
date and notification of change of treatment coincide, the EQ-
5D value will belong to the subsequent state. In sensitivity
analysis 3, we assigned the EQ-5D value to the state prior to
the change.
Table 1. Cost data used in the analysis.
Unit cost Source
LNG-IUS
Consultation (GP 10 mins) £26.67 Curtis 2011/expert opinion
Insertion
GP (20 mins) £53.33 Curtis 2011/expert opinion
Practice nurse (20 mins) £17.00 Curtis 2011/expert opinion
Device cost £88.00 BNF 62
Sterile pack (insertion) £21.63 NICE (inflated to 2011)
Discontinuation
GP (10 mins) £26.67 Curtis 2011/expert opinion
Practice nurse (10 mins) £8.50 Curtis 2011/expert opinion
Sterile pack (removal) £3.77 NICE (inflated to 2011)
Follow-up
6 week review: (GP 10 mins) £26.67 Curtis 2011/expert opinion
3 month: (GP 10 mins) £26.67 Curtis 2011/expert opinion
Usual medical treatment
Progestogen (Cerazette) £8.68 BNF 62
Tranexamic acid (cyclokapron) £14.30 BNF 62
Mefenamic acid (Ponstan) £15.72 BNF 62
Norethisterone £2.18 BNF 62
Combined oral contraceptive (microgynon) £2.82 BNF 62
Methoxyprogesterone acetate injections
(Depo-provera)
£6.01 BNF 62
Consultation: (GP 10 mins) £26.67 Curtis 2011/expert opinion
3 or 6 month review (GP 10 mins) £26.67 Curtis 2011/expert opinion
Discontinuation (GP 10 mins) £26.67 Curtis 2011/expert opinion
Surgery £1720.18 Weighted cost from trial
All costs are presented in 2011 (£) sterling.
doi:10.1371/journal.pone.0091891.t001
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4. We repeated the base case analyses and the three deterministic
analyses (described in 1 to 3 above) but used SF-6D, instead of
EQ-5D to generate QALYs.
The probabilistic sensitivity analysis simultaneously changes all
relevant parameters in the model. For each parameter, a
distribution is assigned and a value for each parameter is
randomly drawn from the assigned distribution. This is repeated
1000 times and the range of incremental cost and QALY results
for LNG-IUS and usual medical treatment are presented on the
cost-effectiveness plane. We used these 1000 values to construct a
cost-effectiveness acceptability curve (CEAC) to illustrate the
probability of LNG-IUS being more cost-effective than usual
medical treatment, across a range of monetary values that
decision-makers may be willing to pay for an additional QALY.
This was carried out using both EQ-5D and SF-6D.
Results
Table 4 presents the base case and deterministic sensitivity
analysis results using EQ-5D. The base case results show that
LNG-IUS costs £100 more than usual medical treatment, as it
costs £430 whilst usual medical treatment costs £330. However,
LNG-IUS also generated 0.067 more QALYs than usual medical
treatment as LNG-IUS generated 1.580 QALYs and usual
medical treatment 1.513 QALYs. The base case results show that
LNG-IUS generates £1600 per additional QALY when compared
to usual medical treatment.
In deterministic sensitivity analyses 1, 2 and 3, which all used
EQ-5D as per base case, the findings supported the base case
results. However, the ICER in each analysis did differ (see Table 4).
Sensitivity analysis 1 and 2 had a slightly less favourable effect,
increasing the ICER to £2030 and £1640 per QALY gained
respectively, whilst sensitivity analysis 3 resulted in a more
favourable effect on the ICER with a reduction to £1510 per
additional QALY.
The results of the probabilistic sensitivity analysis (Figure 2)
illustrate the distribution of the incremental costs and effects (EQ-
5D) from 1000 Monte Carlo simulations. The uncertainty is then
summarised in relation to the changes in the decision-makers
threshold for considering an intervention cost-effective in Figure 3.
It depicts the CEAC, which shows that from £2000 per QALY,
LNG-IUS has a greater probability of being the more cost-
effective intervention. This probability increases to over 90% at
approximately £4000 per QALY.
In sensitivity analysis 4, where the analysis was repeated using
SF-6D instead of EQ-5D, the results are presented in Table 5.
Similar to the base case results LNG-IUS costs £100 more than
usual medical treatment as it costs £430 whilst usual medical
treatment costs £330. However, when SF-6D is used, usual
medical treatment is shown to generate 0.002 more QALYs than
LNG-IUS, as usual medical treatment generated 1.200 QALYs
and LNG-IUS 1.198 QALYs. Therefore, it is shown that usual
medical treatment dominates LNG-IUS. Usual medical treatment
is shown to dominate in all but one of the analyses using SF-6D.
The exception was where EQ-5D values were replaced by SF-6D
for sensitivity analysis 3, in which case LNG-IUS was shown to be
more effective than usual medical treatment and more expensive,
generating an ICER of around £110,000.
The results of the probabilistic sensitivity analysis and the CEAC
using SF-6D are presented in Figures 4 and 5. The CEAC shows
that for any threshold willingness-to-pay per QALY, usual medical
treatment has the greater probability of being the more cost-
effective intervention. This probability is 100% at £0 per QALY
and decreases to 90% at approximately £20,000 per QALY.
Table 2. Health state utility data used in the model.
Health State EQ-5D value PSA Distribution (EQ-5D) SF-6D Value# PSA Distribution (SF-6D)# Source
LNG-IUS
LNG-IUS 0.756 Beta (653, 211) 0.597 Beta (10204, 6883) ECLIPSE trial
Well with LNG-IUS 0.98 Beta (1169, 297) 0.598 Beta (17912, 12061) ECLIPSE trial
Symptomatic with LNG-IUS 0.744 Beta (130, 45) 0.589 Beta (3464, 2418) ECLIPSE trial
Change to usual medical treatment 0.817 Beta (20, 5) 0.596 Beta (1066, 723) ECLIPSE trial
Well with usual medical treatment 0.714 Beta (66, 26) 0.594 Beta (2032, 1390) ECLIPSE trial
No treatment 0.785 Beta (70, 19) 0.604 Beta (2108, 1380) ECLIPSE trial
Surgery 0.620 Linked to post surgery 0.430 Linked to post surgery ECLIPSE trial
Post-surgery 0.827 Beta (59, 12) 0.574 Beta (330, 245) ECLIPSE trial
Usual medical treatment
Usual medical treatment 0.714 Beta (514, 206) 0.603 Beta (9892, 6519) ECLIPSE trial
Well with usual medical treatment 0.728 Beta (528, 197) 0.592 Beta (9664, 6647) ECLIPSE trial
Symptomatic with usual medical
treatment
0.756 Beta (311, 100) 0.606 Beta (5168, 3359) ECLIPSE trial
Change to LNG-IUS 0.694 Beta (49, 21) 0.627 Beta (2494, 1484) ECLIPSE trial
Well with LNG-IUS 0.801 Beta (282, 70) 0.595 Beta (4069, 2766) ECLIPSE trial
No treatment 0.766 Beta (223, 68) 0.586 Beta (3548, 2509) ECLIPSE trial
Surgery 0.619 Linked to post-surgery 0.454 Linked to post surgery ECLIPSE trial
Post-surgery 0.825 Beta (64, 14) 0.606 Beta (2136, 1391) ECLIPSE trial
Utility values are rounded to 3 decimal places. a and b values for the PSA distribution are rounded to the nearest whole number. LNG-IUS; levonorgestrel-releasing
intrauterine system, PSA; probabilistic sensitivity analysis.
#Values used in sensitivity analysis 4.
doi:10.1371/journal.pone.0091891.t002
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Discussion
Main findings
In the primary care setting, treating menorrhagia using LNG-
IUS, costs more but is also more effective than usual medical
treatment. The relative cost-effectiveness of LNG-IUS compared
to usual medical treatment is £1600 per QALY. This means every
additional QALY costs an extra £1600. The deterministic
sensitivity analyses showed the uncertainty in this ICER to be in
the range of £1,560–£2,030 for additional QALY gained. As the
Table 3. Probability parameters used in the analysis.
Probability Parameters Probability PSA distribution
LNG-IUS
LNG-IUS to well with LNG-IUS 0.639 (182, 103) Dirichlet
LNG-IUS to symptomatic with LNG-IUS 0.253 (72, 213)
LNG-IUS to change to usual medical treatment 0.067 (19, 266)
LNG-IUS to no treatment 0.042 (12, 73)
Remain Well with LNG-IUS 1 Fixed
Symptomatic with LNG-IUS to well with LNG-IUS 0 Fixed
Remain symptomatic with LNG-IUS 0.907 (700, 72) Dirichlet
Symptomatic with LNG-IUS to change to usual medical treatment 0.035 (27, 745)
Symptomatic with LNG-IUS to no treatment 0.041 (32, 740)
Symptomatic with LNG-IUS to surgery 0.017 (13, 759)
Remain change to usual medical treatment 0.708 (109, 45) Dirichlet
Change to usual medical treatment to well with usual medical treatment 0.208 (32, 122)
Change to usual medical treatment to no treatment 0.045 (7, 147)
Change to usual medical treatment to surgery 0.039 (6, 148)
Remain well with usual medical treatment 1 Fixed
No treatment to change to usual medical treatment 0 (1, 547) Dirichlet
Remain no treatment 0.984 (540, 8)
No treatment to surgery 0.016 (10, 538)
Surgery to post surgery 1 Fixed
Remain post surgery 1 Fixed
Usual medical treatment
Usual medical treatment to well with usual medical treatment 0.402 (115, 171) Dirichlet
Usual medical treatment to symptomatic with usual medical treatment 0.566 (162, 124)
Usual medical treatment to change to LNG-IUS 0.007 (2, 284)
Usual medical treatment to no treatment 0.024 (7, 279)
Remain Well with usual medical treatment 1 Fixed
Symptomatic with usual medical treatment to well with usual medical treatment 0 Fixed
Remain symptomatic with usual medical treatment 0.901 (1474, 162) Dirichlet
Symptomatic with usual medical treatment to change to LNG-IUS 0.049 (80, 1556)
Symptomatic to no treatment 0.040 (65, 1571)
Symptomatic to surgery 0.010 (17, 1619)
Remain change to LNG-IUS 0.603 (120, 79) Dirichlet
Change to LNG-IUS to well with LNG-IUS 0.312 (62, 137)
Change to LNG-IUS to no treatment 0.045 (9, 190)
Change to LNG-IUS to surgery 0.040 (8, 191)
Remain well with LNG-IUS 1 Fixed
No treatment to change to LNG-IUS 0.001 (1, 852) Dirichlet
Remain no treatment 0.992 (846, 7)
No treatment to surgery 0.007 (6, 847)
Surgery to post surgery 1 Fixed
Post surgery to post surgery 1 Fixed
a and b values for the PSA distribution are rounded to the nearest whole number. LNG-IUS; levonorgestrel-releasing intrauterine system, PSA; probabilistic sensitivity
analysis.
doi:10.1371/journal.pone.0091891.t003
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NICE guidelines recommend new interventions into practice if the
ICER is below £20,000 per QALY, LNG-IUS would be
considered cost-effective and recommended as the primary choice
for women who require treatment, have no preference against
contraception or intrauterine insertion, and no contraindication to
LNG-IUS insertion.
However, the importance of selecting the most appropriate
quality of life instrument is highlighted when the measure used to
assess quality of life is changed in sensitivity analysis 4 from EQ-
Table 4. Base case and deterministic sensitivity analysis results using EQ-5D.
Total costs per
intervention (£)
Total QALYs per
intervention
Incremental cost effectiveness
ratio (ICER) (v usual medical
treatment)
Summary of base case deterministic results
Usual medical treatment 330 1.513 1600
LNG-IUS 430 1.580
Mean Difference 100 0.067
Deterministic sensitivity analysis 1*
Usual medical treatment 330 1.590 2030
LNG-IUS 430 1.643
Mean Difference 100 0.053
Deterministic sensitivity analysis 2#
Usual medical treatment 340 1.513 1640
LNG-IUS 450 1.580
Mean Difference 110 0.067
Deterministic sensitivity analysis 36
Usual medical treatment 330 1.514 1560
LNG-IUS 430 1.582
Mean Difference 100 0.068
Cost are rounded to nearest 10. QALYs are rounded to 3 decimal places QALYS; quality adjusted life year, LNG-IUS; levonorgestrel-releasing intrauterine system, ICER;
incremental cost-effectiveness ratio.
*Deterministic sensitivity analysis 1 = Use median utility values.
#Deterministic sensitivity analysis 2 = Use NICE assumptions.
6Deterministic sensitivity analysis 3 = Assigning EQ-5D completion date utility for change treatment, if change treatment date is the same as EQ-5D completion date.
doi:10.1371/journal.pone.0091891.t004
Figure 2. Results of the probabilistic sensitivity analysis (EQ-5D).
doi:10.1371/journal.pone.0091891.g002
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5D to SF-6D. In sensitivity analysis 4, where utility values from
SF-6D are used rather than EQ-5D, the cost-effectiveness results
differ. In contrast to the findings using EQ-5D, usual medical
treatment is the more cost-effective intervention. Usual medical
treatment was found to dominate LNG-IUS in the base case and
the two deterministic sensitivity analyses. In the third deterministic
analysis, the ICER for LNG-IUS was over £100,000 per QALY
which is much higher than the £20,000/QALY threshold
currently set by NICE, therefore usual medical treatment would
be recommended for implementation in clinical practice.
The difference in the cost-effectiveness results derived by using
the alternative measures to value quality of life has a considerable
impact on the cost-effectiveness decision. The different measures
did not just change the strength of cost-effectiveness of the same
treatment, but the most cost-effective treatment itself changed.
Therefore the recommendation to decision-makers would differ
depending on the quality of life instrument used.
Figure 3. Cost-effectiveness acceptability curves for usual medical treatment and LNG-IUS using EQ-5D.
doi:10.1371/journal.pone.0091891.g003
Table 5. Sensitivity analysis 4 results using SF-6D.
Total costs per
intervention (£)
Total QALYs per
intervention
Incremental cost effectiveness
ratio (ICER) (v usual medical
treatment)
Summary of base case deterministic results
Usual medical treatment 330 1.200 Dominates
LNG-IUS 430 1.198
Mean Difference 100 20.002
Deterministic sensitivity analysis 4.1*
Usual medical treatment 330 1.215 Dominates
LNG-IUS 430 1.215
Mean Difference 100 0
Deterministic sensitivity analysis 4.2#
Usual medical treatment 340 1.200 Dominates
LNG-IUS 450 1.198
Mean Difference 110 20.002
Deterministic sensitivity analysis 4.36
Usual medical treatment 330 1.198 112,340
LNG-IUS 430 1.199
Mean Difference 100 0.001
Cost are rounded to nearest 10. QALYs are rounded to 3 decimal places. QALYS; quality adjusted life year, LNG-IUS; levonorgestrel-releasing intrauterine system, ICER;
incremental cost-effectiveness ratio.
*Deterministic sensitivity analysis 1 = Use median utility values.
#Deterministic sensitivity analysis 2 = Use NICE assumptions.
6Deterministic sensitivity analysis 3 = Assigning SF-6D completion date utility for change treatment if change treatment date is the same as SF-6D completion date.
doi:10.1371/journal.pone.0091891.t005
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Strengths and limitations
The strength of this cost-utility analysis is that it is based on data
from the largest multi-centre randomised trial undertaken for
menorrhagia. Since the treatment is aimed at managing the
condition, the changes in both quality of life and costs throughout
the woman’s treatment journey are critical to the analysis and
these are most appropriately captured by using the trial data to
populate a model. The model structure was developed based on
the women’s pathway data from the trial and supported by the
advice of expert clinicians. All assumptions were agreed by the
team in the model development stage prior to analysis. A further
strength is that all data on resource use and outcomes were
collected prospectively alongside the trial and the economic
evaluation was an integral component of the trial design from the
outset.
Some limitations exist as a result of some of the assumptions
required for the model. For instance it was assumed that women
are ‘well’ if they do not change treatment. Nonetheless this
assumption is mitigated by the fact that if women enter the ‘well’
state, but are not well, it will be reflected in the overall utility value
for ‘well’.
A further potential limitation is that baseline differences in
quality of life data at the outset of the trial were not adjusted to be
the same. The initial EQ-5D score in the LNG-IUS group was
0.042 higher at the outset of the trial than in usual medical
treatment and this difference is significant (p,0.05). These data
are based on individuals who have been randomised, so it is
Figure 4. Results of the probabilistic sensitivity analysis (SF-6D).
doi:10.1371/journal.pone.0091891.g004
Figure 5. Cost-effectiveness acceptability curves for usual medical treatment and LNG-IUS using SF-6D.
doi:10.1371/journal.pone.0091891.g005
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assumed that this difference occurred by chance and it does not
follow that this initial difference between groups would be
sustained over the 2 year time horizon in the absence of treatment.
Adjustment for baseline therefore risks imposing a difference at
every point in time over the time period of analysis.
If we did adjust fully for the difference in baseline we would
show LNG-IUS to be less effective than usual medical treatment,
but in so doing, the assumption would be imposed that the
difference would be maintained over the time horizon. This would
not be an appropriate assumption since the probability of
regression to the mean over time would be ignored. It is therefore
acknowledged that the base case results might be slightly over
optimistic but it is not clear how much of an adjustment, if any,
would be appropriate.
Comparison with other studies
To our knowledge, this is the first study to conduct a cost-utility
analysis using prospectively collected primary data from a trial to
directly compare LNG-IUS and usual medical treatment for
women with menorrhagia. Other economic evaluations of LNG-
IUS have been carried out, however none have drawn a
comparison of LNG-IUS directly against usual treatment using
primary data. Another primary study has shown LNG-IUS to be
cost-effective, but the comparator was hysterectomy and the study
is considered to have methodological flaws [15;10]. Other studies
have compared alternative treatments using model based analyses
and secondary data from reviews [2;16;17] although, the studies
typically compared LNG-IUS, various oral treatments and various
surgical techniques against one another. Two of these showed
LNG-IUS to be the most cost-effective intervention [2;16]. The
remaining study suggested that hysterectomy was the optimal
intervention but the authors acknowledged that insufficient
published data on the effectiveness of LNG-IUS were available
at the time [17]. Although LNG-IUS is shown to be cost-effective
against surgical interventions in these studies, it does not provide
evidence for LNG-IUS being cost-effective against usual pharma-
ceutical treatment.
Implications and Further Research
The results, based on the decision-maker recommended EQ-
5D, provide clear evidence in support of the NICE guidelines that
recommend LNG-IUS be considered the primary treatment for
menorrhagia. The main objective of this study was to provide
evidence to decision-makers on the cost-effectiveness of two
treatments for menorrhagia, the primary results therefore are
based on EQ-5D. However, as SF-6D data were also collected, the
use of this measure was deemed worthy of exploration in the
sensitivity analysis.
When SF-6D is used to generate QALYs, the main base case
results are reversed and usual medical treatment is shown to be the
more cost-effective intervention. Hence the recommendation to
decision-makers differs depending on the outcome measure used.
The conflicting findings suggest that these measures may be
capturing different aspects of quality of life which clearly has an
impact on the results. Reasons why these instruments produce
different results have been further explored by other authors
(Brazier et al [18] and Whitehurst and Bryan [19]) but this does
not help to guide which instrument is more appropriate within the
context of menorrhagia, particularly when the results are so
sensitive to that choice. It may well be that neither instrument is
appropriate, with their focus exclusively on health-related quality
of life, and consideration needs to be given to alternative measures
which is evidenced in a recent quality of life review [20]. Future
research might appropriately explore alternative methods for
measuring outcomes that are important to women and these might
include outcomes which are not based solely on health related
quality of life.
This manuscript reports the 2 year follow-up and was
commissioned by the NIHR-HTA for an analysis at 2 years. As
the condition is chronic and continues until menopause, further
economic evaluations with longer term follow-up will be reported
and published as and when they are available.
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